Our successful proprietary antibody humanisation technique and expertise has helped to bring several humanised antibody drugs to the market, including Keytruda®, Tysabri®, and Actemra®

Tysabri (natalizumab), humanised by us on behalf of Elan/Biogen Idec, is a world-leading monoclonal antibody treatment for multiple sclerosis and Crohn’s disease.

Our work to humanise Actemra (tocilizumab) for Roche has helped to put a treatment for rheumatoid arthritis on the market, and patients in over 90 countries now benefit from the drug.

We also helped to develop Keytruda (pembrolizumab), a leading cancer drug.

All Case Studies